This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Amantadine
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
<applet load="" size="480" color="" frame="true" spin="on" Scene ="Amantadine/Amantadine/1" align="right" caption="Amantadine, also known as Symmetrel"/> | <applet load="" size="480" color="" frame="true" spin="on" Scene ="Amantadine/Amantadine/1" align="right" caption="Amantadine, also known as Symmetrel"/> | ||
===Better Known as: Symmetrel=== | ===Better Known as: Symmetrel=== | ||
| - | * Marketed By: | + | * Marketed By: Endo Pharmaceuticals |
* Major Indication: [[Influenza]] Infection | * Major Indication: [[Influenza]] Infection | ||
* Drug Class: [[M2 Proton Channel]] Inhibitor | * Drug Class: [[M2 Proton Channel]] Inhibitor | ||
Revision as of 12:15, 7 December 2010
|
Better Known as: Symmetrel
- Marketed By: Endo Pharmaceuticals
- Major Indication: Influenza Infection
- Drug Class: M2 Proton Channel Inhibitor
- Date of FDA Approval): 1966
- 1994 Sales: N/A
- Importance: One of the the first treatments approved by the FDA and the first approved for treatment of Influenza Infections. Nearly 100% of influenza viruses had developed resistance to rimantadine, and it is no longer recommended as a treatment for the flu. Interestingly, in 1969 it was also discovered that Amantadine helped reduce the symptoms of Parkinson's Disease.
- The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information
Mechanism of Action
Pharmacokinetics
| M2 Proton Channel Inhibitor Pharmacokinetics[1][2] | ||||||
|---|---|---|---|---|---|---|
| Parameter | Rimantadine | Amantadine | ||||
| Tmax (hr) | 4.3 | 2.5 | ||||
| Cmax (ng/ml) | 310 | 402 | ||||
| Bioavailability (%) | >90 | >90 | ||||
| Protein Binding (%) | 40 | 67 | ||||
| T1/2 (hr) | 27.7 | ~15 | ||||
| AUC (ng/ml/hr) | 11917 | 5420 | ||||
| Dosage (mg) | 100 | 100 | ||||
| Metabolism | Negligible | Negligible | ||||
References
- ↑ Anderson EL, Van Voris LP, Bartram J, Hoffman HE, Belshe RB. Pharmacokinetics of a single dose of rimantadine in young adults and children. Antimicrob Agents Chemother. 1987 Jul;31(7):1140-2. PMID:3662473
- ↑ Wang P, Liang YZ, Chen BM, Zhou N, Yi LZ, Yu Y, Yi ZB. Quantitative determination of amantadine in human plasma by liquid chromatography-mass spectrometry and the application in a bioequivalence study. J Pharm Biomed Anal. 2007 Mar 12;43(4):1519-25. Epub 2006 Dec 6. PMID:17156962 doi:10.1016/j.jpba.2006.10.044
